Amgen Defends Its Turf as Competition Looms for Anemia Drug
642785
As a looming battle with Roche approaches, Amgen is preparing to defend its anemia franchise, now worth $7 billion a year, through pricing and lawsuits.
754072
Genzyme Corp.'s planned takeover of New York cancer drug maker Bioenvision Inc. has already hit a bump: A key Bioenvision shareholder is calling the deal a lowball offer and digging in against it.
520589
Investors are discouraged after it releases the latest data for its top drug.
147168
The approval of a new drug is a long-term opportunity.
174211
A drug manufacturer has been found to infringe patents licensed by the maker of a rival drug.
145690
A senior Medicare official said the  case for cutting the use of controversial anemia drugs sold by  Amgen Inc and Johnson & Johnson has become stronger since the  agency decided last year to cut payments for their use in  cancer patients.
97646
The Motley Fool - As investors waited anxiously for Amgen's (Nasdaq: AMGN - News) earnings report, the United Kingdom's high court snuck in with a stinker. It ruled that Transkaryotic Therapies (Nasdaq: TKTX - News) and Sanofi-Aventis (NYSE: SNYT - News) did not infringe on the patent for EPO, Amgen's anemia treatment (which accounts for 27% of its sales), and ruled the patent invalid.
726765
Amgen Inc. has added a warning to  its anemia drug, Aranesp, for kidney dialysis and cancer  patients after studies on similar drugs showed higher doses can  cause blood clots and death, the company said a letter released  on Friday.
390937
A rare bidding war between two Cambridge biotechnology powerhouses heated up yesterday after Genzyme Corp. said it might raise its offer for a Canadian drug company, hoping to snatch it away from another suitor, Millennium Pharmaceuticals Inc.
651193
Amgen Inc. said yesterday a jury ruled in its favor in a patent dispute over an anemia treatment whose possible US launch could challenge the drug maker's top-selling drug.
543431
Drugs that treat anemia caused by kidney failure provide important benefits despite the risks for some patients at high doses, Amgen Inc. told a U.S. advisory panel on Tuesday.
764344
The anti-industry crusader targets pharmaceuticals.
272534
BOSTON (CBS.MW) -- With the threat of generic competition looming over the pharmaceutical industry, Pfizer Inc. declared on Tuesday that the strength and breadth of its drugs under development will give the company an edge over its rivals.
271163
GAITHERSBURG, Md. - Amgen Inc. and Johnson &amp; Johnson's anemia drugs don't need changes in recommended doses to protect the safety of kidney patients, US advisers said.
700955
If the plans of the Turku-based company Biotie Therapies and the Californian Somaxon Pharmaceuticals work out, Americans could soon have access to a new medicine that is claimed to work against different types ...
640534
Its failure to acquiesce to the FDA's request means the competition is going forward as this drugmaker's product stays stagnant.
162445
Rivals CVS and Rite Aid have a bitter pill to swallow as Walgreen stays strong.